GSK’s decision to switch patients from its brand-name Flovent inhaler to an authorized generic is an “insidious” tactic that “may cause millions of children” to lose access to their asthma and allergy medication, Sen. Elizabeth Warren (D-MA) said in a letter to the company released on Monday.
The move by GSK in October to discontinue Flovent came just prior to the end of the Medicaid rebate cap in January, which effectively would have forced GSK to pay Medicaid for covering the inhaler because the rebates were so high.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.